May 2, 2026 — The U.S. Food and Drug Administration (FDA) has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug, allowing more patients to use the medication before its formal market approval. This is the world’s first RAS gene mutation inhibitor, and clinical trials have demonstrated its potential to significantly extend survival in metastatic pancreatic cancer patients.

A Breakthrough for the “King of Cancers”

Pancreatic cancer is known as the “king of cancers” — one of the most aggressive malignancies with a five-year survival rate of less than 10%. Over 90% of pancreatic cancer patients carry KRAS gene mutations, a target long considered “undruggable.”

Daraxonrasib, developed by Revolution Medicines, is the first drug to demonstrate in clinical trials that it can effectively inhibit KRAS mutations and extend survival in pancreatic cancer patients. In Phase II trials, patients receiving the drug showed significantly improved median survival compared to historical controls.

Expanded Access Program

The FDA’s expanded access approval allows critically ill patients who cannot benefit from other treatments to use the drug before formal market approval. This decision means eligible pancreatic cancer patients can gain earlier access to this innovative therapy.

Notably, the wife of former Senator Ben Sasse is among the early beneficiaries of the drug. The Sasse family has publicly supported the drug’s development and shared positive responses on social media.

Scientific Breakthrough

RAS proteins play a critical role in cell signaling, and their mutations drive uncontrolled cancer cell growth. For decades, scientists struggled to develop RAS-targeting drugs because the protein’s smooth structure lacked traditional drug-binding sites, making it seem nearly impossible to target.

In recent years, advances in structural biology and drug design have finally enabled strategies to target specific RAS mutations (such as KRAS G12C and G12D). Daraxonrasib is the product of this scientific breakthrough.

Next Steps in Approval

Revolution Medicines is currently advancing daraxonrasib through Phase III clinical trials. If results meet expectations, the company expects to submit a New Drug Application (NDA) to the FDA within 12-18 months.

Wall Street analysts are optimistic about the drug’s commercial prospects. Pancreatic cancer affects over 500,000 new patients globally each year, and effective targeted treatment options remain extremely limited. If approved, daraxonrasib is projected to generate billions in annual revenue.

Medical Community Response

The American Society of Clinical Oncology (ASCO) issued a statement calling daraxonrasib’s progress “one of the most breakthrough developments in pancreatic cancer treatment.” Oncology experts at UW Health expressed enthusiasm for the drug’s potential in interviews.

Sources: The Washington Post, Reuters, CBS News

The U.S. Food and Drug Administration has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug developed by Revolution Medicines, according to The New York Times and Reuters. The decision opens the door for more patients awaiting treatment to receive a therapy that has demonstrated significant efficacy in clinical trials.

A Breakthrough Therapy

Daraxonrasib is a targeted inhibitor directed at the KRAS G12D mutation. KRAS mutations are among the most common driver alterations in pancreatic cancer, found in approximately 35% to 40% of pancreatic ductal adenocarcinoma cases. For decades, the KRAS protein was considered “undruggable” due to its structural characteristics, but a new generation of covalent inhibitors has changed that landscape.

Reuters reports that in early-stage clinical trials, daraxonrasib caused significant tumor shrinkage in some patients with advanced pancreatic cancer. Notably, the spouse of former Senator Ben Sasse has shown encouraging results on the drug, drawing widespread public attention.

What Expanded Access Means

The FDA’s expanded access program — also known as “compassionate use” — allows unapproved drugs to be used by patients with serious or life-threatening conditions who cannot enroll in clinical trials. The approval of this pathway means more patients who are ineligible for trial participation can gain early access to treatment.

The Washington Post notes that the speed of the expanded access approval reflects the FDA’s strong confidence in the drug’s efficacy data. While such approvals typically take several weeks, this one was processed in under two weeks.

The Challenge of Pancreatic Cancer

Pancreatic cancer is often called the “king of cancers” and ranks as the fourth leading cause of cancer-related death in the United States. Due to its subtle early symptoms, difficulty in detection, and limited treatment options, the five-year survival rate has long hovered around just 12%.

Revolution Medicines’ Chief Medical Officer stated: “We are pleased to work with the FDA to give more patients in desperate need the opportunity to receive daraxonrasib. This is an important step toward transforming the pancreatic cancer treatment landscape.”

Market Outlook

Industry analysts project that if daraxonrasib continues to demonstrate positive data in later-stage trials, it could receive full FDA approval by 2027. At that point, the KRAS-targeted therapy market is expected to reach tens of billions of dollars, covering indications in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

Source: The New York Times · Reuters · USA Today

The U.S. Food and Drug Administration (FDA) approved expanded early access for the experimental pancreatic cancer drug daraxonrasib on May 1, 2026. This decision brings new hope for late-stage pancreatic ductal adenocarcinoma (PDAC) patients and has sparked enthusiastic discussion in the medical community about the broad potential of targeted therapy in oncology.

Drug Background

Daraxonrasib is an experimental drug targeting the KRAS G12D mutation. KRAS gene mutations are extremely common in pancreatic cancer, with approximately 30-40% of PDAC patients carrying this mutation. For decades, KRAS was considered an “undruggable” target until recent breakthroughs in targeted therapy technology made substantive progress possible.

According to the New York Times, the drug has shown encouraging efficacy in early clinical trials — some late-stage pancreatic cancer patients experienced significant tumor shrinkage, with a few cases achieving complete remission. This result represents a milestone in pancreatic cancer treatment, as the disease has long been called the “king of cancers” with a five-year survival rate of less than 13%.

Expanded Access Program

The FDA’s approval is for an “Expanded Access” protocol, also known as “Compassionate Use.” This mechanism allows patients with serious or life-threatening diseases to access experimental drugs before they receive full regulatory approval.

According to the Washington Post, CBS News reported that former Senator Ben Sasse is one of the beneficiaries of this drug, sharing his treatment experience publicly. This high-profile political figure’s involvement has further elevated public awareness of the drug.

Professional medical journals including OncLive and Targeted Oncology have both covered this development in detail, noting that the approval of the expanded access protocol means the drug has received the FDA’s basic safety endorsement, paving the way for large-scale clinical trials and eventual market approval.

The Pancreatic Cancer Treatment Challenge

Pancreatic cancer is one of the deadliest cancers globally, characterized by difficulties in early diagnosis, poor response to traditional chemotherapy, and low surgical resection rates. According to the American Cancer Society, approximately 66,000 people in the United States are expected to be diagnosed with pancreatic cancer in 2026, with about 51,000 dying from the disease.

Mayo Clinic’s recently developed REDMOD AI system has demonstrated the ability to identify pancreatic cancer signatures from CT scans an average of 16 months before diagnosis (as reported in today’s AI & Tech section), while daraxonrasib’s progress represents an important breakthrough on the treatment side. The combination of AI-assisted diagnosis and targeted therapy may be reshaping the entire pancreatic cancer care ecosystem.

Looking Ahead

Analysts note that if daraxonrasib can confirm its efficacy in large-scale Phase III clinical trials, it would represent a major breakthrough in pancreatic cancer targeted therapy — the first in decades. Currently, multiple pharmaceutical companies are competing in this space, including other targeted drugs aimed at KRAS G12C mutations.

The expanded access approval means eligible patients can access treatment before the drug’s formal market approval, but it also requires doctors and patients to fully understand the drug’s experimental nature and potential risks.

Source: New York Times | USA Today | Washington Post